重组人血管内皮抑制素在乳腺癌治疗中的研究进展

Research Progress on Recombinant Human Endostatin in the Treatment of Breast Cancer

大量研究表明抗血管生成治疗与放疗、化疗、免疫治疗及其他抗肿瘤药物联合使用可发挥协同增效作用。重组人血管内皮抑制素(恩度)是一种泛靶点类抗肿瘤血管生成靶向药物,其可通过抑制或调节肿瘤血管生成的多条信号通路,抑制内皮细胞的增殖、迁移,同时诱导内皮细胞的凋亡,抑制血管通透性的增加,使肿瘤血管“正常化”,重塑肿瘤微环境,从而改善肿瘤的综合治疗疗效,抑制肿瘤的生长和转移。近年来,恩度用于治疗乳腺癌的研究逐渐增多,并取得了可观的治疗效果,且不良反应小。全文就恩度的作用机制及其在乳腺癌治疗中的研究进展作一综述,旨在探讨恩度在乳腺癌治疗中的应用前景及优化手段,以期为乳腺癌患者尤其是三阴性乳腺癌患者带来更长远的生存获益。

Studies have shown that anti-angiogenic therapy can exert synergistic effects when combined with radiotherapy, chemotherapy, immunotherapy and other antineoplastic therapies. Recombinant human endostatin(Endostar) is an anti-angiogenic agent with multi-targets. It can inhibit or regulate multiple signal pathways related to tumor angiogenesis, inhibiting the proliferation and migration of endothelial cells, inducing apoptosis of endothelial cells, reducing vascular permeability, “normalizing” tumor blood vessels and reshaping the tumor microenvironment, thereby to inhibit tumor growth and metastasis and to improve the therapeutic efficacy of cancer patients. In recent years, Endostar is widely used in treatment of breast cancer and considerable therapeutic effects have been achieved with small side effects. This article reviews the mechanism of action of Endostar and its application in treatment of breast cancer, especially for patients with triple-negative breast cancer.